)
Visual21 Nov 2025
Data center suppliers
Janux Therapeutics (JANX) investor relations material
Janux Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Clinical-stage biopharma focused on novel immunotherapies for cancer and autoimmune diseases, with lead programs JANX007 (PSMA-TRACTr) and JANX008 (EGFR-TRACTr) in Phase 1 trials and a preclinical ARM platform candidate showing promising results.
Ongoing enrollment for JANX007 (prostate cancer) and JANX008 (solid tumors) Phase 1 trials, with data updates expected in Q4 2025.
Multiple new drug candidates are expected to enter clinical trials in 2026, leveraging proprietary TRACTr, TRACIr, and ARM platforms.
No product revenue to date; all revenue derived from a collaboration with Merck, with research obligations now completed.
Net loss of $81.7 million for the nine months ended September 30, 2025, compared to $48.8 million in the prior year period.
Financial highlights
Cash, cash equivalents, restricted cash, and short-term investments totaled $989.8 million as of September 30, 2025.
Research and development expenses increased to $94.3 million for the nine months ended September 30, 2025, up from $47.6 million year-over-year, driven by higher preclinical and manufacturing costs.
General and administrative expenses decreased to $30.9 million for the nine months ended September 30, 2025, from $32.8 million in the prior year, mainly due to lower stock-based compensation.
Net loss for Q3 2025 was $24.3 million, an improvement from $28.1 million in Q3 2024.
Collaboration revenue was $10.0 million for both the three and nine months ended September 30, 2025, primarily from a $10.0 million milestone under the Merck agreement.
Outlook and guidance
Expenses and operating losses are expected to increase substantially as research and development activities expand.
Existing cash and investments are expected to fund operations for at least the next 12 months.
Additional clinical data for JANX007 and JANX008 will be presented in Q4 2025.
New clinical candidates from TRACTr, TRACIr, and ARM platforms are expected to enter trials in 2026.
Projected cash runway with current burn?
Which new candidates enter clinic next year?
Source of Q3 2025 collaboration revenue?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Janux Therapeutics earnings date
Q4 202526 Feb, 2026
Next Janux Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to create targeted therapies that activate the immune system specifically within the tumor microenvironment, minimizing systemic side effects. Janux Therapeutics is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage